| Literature DB >> 34534465 |
Liwei Cao1, Chen Huang2, Daniel Cui Zhou3, Yingwei Hu1, T Mamie Lih1, Sara R Savage2, Karsten Krug4, David J Clark1, Michael Schnaubelt1, Lijun Chen1, Felipe da Veiga Leprevost5, Rodrigo Vargas Eguez1, Weiming Yang1, Jianbo Pan1, Bo Wen2, Yongchao Dou2, Wen Jiang2, Yuxing Liao2, Zhiao Shi2, Nadezhda V Terekhanova3, Song Cao3, Rita Jui-Hsien Lu3, Yize Li3, Ruiyang Liu3, Houxiang Zhu3, Peter Ronning3, Yige Wu3, Matthew A Wyczalkowski3, Hariharan Easwaran6, Ludmila Danilova7, Arvind Singh Mer8, Seungyeul Yoo9, Joshua M Wang10, Wenke Liu10, Benjamin Haibe-Kains11, Mathangi Thiagarajan12, Scott D Jewell13, Galen Hostetter13, Chelsea J Newton13, Qing Kay Li1, Michael H Roehrl14, David Fenyö10, Pei Wang9, Alexey I Nesvizhskii5, D R Mani4, Gilbert S Omenn15, Emily S Boja16, Mehdi Mesri16, Ana I Robles16, Henry Rodriguez16, Oliver F Bathe17, Daniel W Chan18, Ralph H Hruban19, Li Ding20, Bing Zhang21, Hui Zhang22.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient survival. Toward understanding the underlying molecular alterations that drive PDAC oncogenesis, we conducted comprehensive proteogenomic analysis of 140 pancreatic cancers, 67 normal adjacent tissues, and 9 normal pancreatic ductal tissues. Proteomic, phosphoproteomic, and glycoproteomic analyses were used to characterize proteins and their modifications. In addition, whole-genome sequencing, whole-exome sequencing, methylation, RNA sequencing (RNA-seq), and microRNA sequencing (miRNA-seq) were performed on the same tissues to facilitate an integrated proteogenomic analysis and determine the impact of genomic alterations on protein expression, signaling pathways, and post-translational modifications. To ensure robust downstream analyses, tumor neoplastic cellularity was assessed via multiple orthogonal strategies using molecular features and verified via pathological estimation of tumor cellularity based on histological review. This integrated proteogenomic characterization of PDAC will serve as a valuable resource for the community, paving the way for early detection and identification of novel therapeutic targets.Entities:
Keywords: CPTAC; KRAS; endothelial cell; glycoproteins; immune-cold tumors; kinase inhibitors; neoplastic cellularity; pancreatic ductal adenocarcinoma; proteogenomics; tumor subtyping
Mesh:
Substances:
Year: 2021 PMID: 34534465 PMCID: PMC8654574 DOI: 10.1016/j.cell.2021.08.023
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 66.850